Rhinomed (ASX:RNO) Institutional Ownership : 0.52% (As of Jun. 04, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Rhinomed Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Rhinomed's institutional ownership is 0.52%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Rhinomed's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Rhinomed's Float Percentage Of Total Shares Outstanding is 0.00%.

Rhinomed Institutional Ownership Historical Data

The historical data trend for Rhinomed's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhinomed Institutional Ownership Chart

Rhinomed Historical Data

The historical data trend for Rhinomed can be seen below:

	2019-09-30	2019-10-31	2019-11-30	2019-12-31	2020-01-31
Institutional Ownership	0.45	0.56	0.56	0.56	0.52

Rhinomed Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Rhinomed (ASX:RNO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rhinomed Ltd (ASX:RNO) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

RHNMF:USA

Address

132 Gwynne Street, Level 1, Cremorne, VIC, AUS, 3121

Website

https://www.rhinomed.global

Rhinomed Ltd is a medical technology company, with a patented nasal technology platform. It is engaged in the research, development and commercialization of consumer and medical devices including nasal, respiratory and nasal drug delivery technologies. It operates in one segment which is the identification, acquisition, and commercialization of late-stage consumer therapeutic and medical delivery technologies. The products of the company involve Rhinoswab, Mute, Turbine and Rhinoswab Junior. It operates geographically within North, Central, and South America, Asia-Pacific, Europe, Middle East, and Africa. The company earns majority of its revenue from Asia-Pacific.

Rhinomed (ASX:RNO) Headlines

No Headlines